Skip to content
sellModerate cluster of 410b5-1 plan

Richard S Geary sold $6.8M of IONS

EVP, Chief Development Officer at IONIS PHARMACEUTICALS INC. 90,929 shares at an average of $75.11, traded Oct 31, 2025, filed Nov 3, 2025.

Warning score
40
Value
$6.8M
90,929 shares
Holdings after
59,657
-80% from before
From 52-week low
+191%
low $25.51, close $74.30
From 52-week high
0%
high $74.30, as of Oct 31, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $6.8M at market
    +25
  • Share of holdings sold
    Sold 80% of holdings
    +20
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IONSOct 9, 2026 · close 45.28
Since filing Nov 3, 2025: -38.5%SPY +15.2% · excess -53.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000874015-25-000270, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 31, 2025MOption exercise
Common Stock10b5-1
+34,585$60.89$2.1M114,242Nov 3, 2025
Oct 31, 2025SOpen-market sale
Common Stock10b5-1
-34,585$75.11$2.6M79,657Nov 3, 2025
Oct 31, 2025MOption exercise
Common Stock10b5-1
+34,664$56.78$2.0M114,321Nov 3, 2025
Oct 31, 2025SOpen-market sale
Common Stock10b5-1
-34,664$75.11$2.6M79,657Nov 3, 2025
Oct 31, 2025SOpen-market sale
Common Stock10b5-1
-20,000$75.11$1.5M59,657Nov 3, 2025
Nov 3, 2025MOption exercise
Common Stock10b5-1
+775$56.78$44k60,432Nov 3, 2025
Nov 3, 2025SOpen-market sale
Common Stock10b5-1
-775$75.05$58k59,657Nov 3, 2025
Nov 3, 2025MOption exercise
Common Stock10b5-1
+905$60.89$55k60,562Nov 3, 2025
Nov 3, 2025SOpen-market sale
Common Stock10b5-1
-905$75.05$68k59,657Nov 3, 2025
Oct 31, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-34,664$0.00$016,443Nov 3, 2025
Nov 3, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-775$0.00$015,668Nov 3, 2025
Oct 31, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-34,585$0.00$019,876Nov 3, 2025
Nov 3, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-905$0.00$018,971Nov 3, 2025

Related signals

Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
40Moderate
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
C Frank Bennett
EVP, Chief Scientific Officer
$6.7M
85,089 shares
-51%
18Weak
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Joseph Baroldi
EVP, Chief Business Officer
$531k
6,659 shares
-15%
30Weak
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Shannon L. Devers
EVP, Chief Human Resources Ofc
$1.6M
20,106 shares
-47%
40Moderate
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Allene M. Diaz
director
$4.4M
54,878 shares
-94%
40Moderate
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
C Frank Bennett
EVP, Chief Scientific Officer
$7.1M
85,089 shares
-85%
48Moderate
IONSsell 4
IONIS PHARMACEUTICALS INC
C Frank Bennett
EVP, Chief Scientific Officer
$488k
5,885 shares
-6%
52Moderate
IONSsell 4
IONIS PHARMACEUTICALS INC
Joseph Baroldi
EVP, Chief Business Officer
$439k
5,296 shares
-10%
48Moderate
IONSsell 4
IONIS PHARMACEUTICALS INC
Brian Birchler
EVP, Corp and Development Ops
$513k
6,179 shares
-9%
29Weak
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Shannon L. Devers
EVP, Chief Human Resources Ofc
$323k
3,977 shares
-15%
35Weak
IONSsell 4
IONIS PHARMACEUTICALS INC
C Frank Bennett
EVP, Chief Scientific Officer
$675k
8,977 shares
-9%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Richard S Geary sold $6.8M of IONS | InsiderTell